Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2016, Pages

  Kayssi, Ahmed ^a   Al Atassi, Talal ^b   Oreopoulos, George ^a   Roche Nagle, Graham ^a   Tan, Kong Teng ^a   Rajan, Dheeraj K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPUTATION; AMPUTATION FREE SURVIVAL; ANKLE BRACHIAL INDEX; CRITICAL LIMB ISCHEMIA; DATA EXTRACTION; DEVICE COMPARISON; DRUG ELUTING CARDIOVASCULAR STENT; HUMAN; INFORMATION RETRIEVAL; INTERMITTENT CLAUDICATION; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SURVIVAL; SYSTEMATIC REVIEW; DRUG ELUTING STENT; FEMORAL ARTERY; LOWER LIMB; META ANALYSIS; MORTALITY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TIBIAL ARTERY; TIME FACTOR; VASCULAR PATENCY; VASCULARIZATION;

PACLITAXEL;

AMPUTATION; ANGIOPLASTY, BALLOON; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; LOWER EXTREMITY; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIBIAL ARTERIES; TIME FACTORS; VASCULAR PATENCY;

EID: 84982706108     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011319.pub2     Document Type: Review

References (68)

1. A prospective, multi-centre, randomized controlled, first in man study to assess the safety and performance of the Passeo-18 Lux paclitaxel releasing PTA balloon catheter vs. the uncoated Passeo 18 balloon catheter in patients with stenosis and occlusion of the femoropopliteal arteries (BIOLUX P-I). clinicaltrials.gov/ct2/show/NCT01221610 (accessed 15 August 2015).
2. Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. Journal of Endovascular Therapy 2015;22:14-21.
3. Tepe G, Schulte K-L, Zeller T, Lammer J, Pfaffinger P, Schmidt A, et al. Six-month results of the BIOLUX P-I first in man study comparing a paclitaxel-releasing balloon catheter versus an uncoated balloon catheter in femoropopliteal lesions. Cardiovascular and Interventional Radiology 2012; Vol. 35:S264-5.
4. Zeller T, Lammer J, Rastan A, Schulte K, Tepe G, Scheinert D. Twelve-month results of the BIOLUX P-I first-in-man study comparing a paclitaxel-releasing balloon catheter versus an uncoated catheter in femoropopliteal lesions. Vasa - Journal of Vascular Diseases 2013;42(Suppl 84):FV 9.7.
5. BIOTONIK's - first in men study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo 18 balloon catheter in subjects requiring revascularization of infrapopliteal arteries (BIOLUX P-II). clinicaltrials.gov/ct2/show/NCT01867736 (accessed 15 August 2015).
6. Deloose K, Zeller T, Scheinert D, Beschorner U. BIOLUX P-II: a randomized clinical trial of Passeo-18 Lux DRB vs POBA for the treatment of infrapopliteal artery lesions. Journal of the American College of Cardiology 2014; Vol. 64, issue Suppl B.
7. Scheinert D, Brodmann M, Zeller T, Bosiers M, Peeters P, Karl-Ludwig S, et al. BIOLUX P-II: a randomized clinical trial of Passeo-18 lux drug releasing balloon versus plain old balloon angioplasty for the treatment of infrapopliteal artery lesions. Journal of the American College of Cardiology 2014;64(11 Suppl 1):B79.
8. Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation 2013;128(6):615-21.
9. Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. Journal of Endovascular Therapy 2012;19(5):571-80.
10. Fanelli F, Cannavale A, Corona M, Lucatelli P, Wlderk A, Salvatori FM. The "DEBELLUM" - lower limb multilevel treatment with drug eluting balloon - randomized trial: 1-year results. Journal of Cardiovascular Surgery 2014;55(2):207-16.
11. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118(13):1358-65.
12. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. Journal of the American College of Cardiology 2014;64(15):1568-76.
13. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. Trials 2014;15:63.
14. Laird JR, Schneider P, Tepe G, Brodmann M, Zeller T, Metzger C, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions 24-month results of IN.PACT SFA. Journal of the American College of Cardiology 2015;66(21):2329-38.
15. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015;131(5):495-502.
16. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC. Cardiovascular Interventions 2014;7(1):10-9.
17. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. New England Journal of Medicine 2015;373(2):145-53.
18. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circulation. Cardiovascular Interventions 2012;5(6):831-40.
19. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC. Cardiovascular Interventions 2015;8(1):102-8.
20. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New England Journal of Medicine 2008;358(7):689-99.
21. Cotavance™ Paclitaxel-coated balloon versus uncoated balloon angioplasty for treatment of in-stent restenosis in SFA and popliteal arteries COPA CABANA Study. clinicaltrials.gov/ct2/show/NCT01594684 (accessed 15 August 2015).
22. Liistro F, Angioli P, Porto I, Ricci L, Ducci K, Grotti S, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. Journal of Endovascular Therapy 2014;21(1):1-8.
23. Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC. Cardiovascular Interventions 2013;6(12):1295-302.
24. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosIs and maintain vessel patency: a pilot study of anti-restenosis treatment. clinicaltrials.gov/ct2/show/NCT01366482 (accessed 15 August 2015).
25. European study of POBA versus Cotavance paclitaxel coated balloon for the treatment of infrapopliteal lesions in critical limb ischemia. clinicaltrials.gov/ct2/show/NCT01260870 (accessed 15 August 2015).
26. Femoral artery in-stent restenosis (FAIR) trial. clinicaltrials.gov/ct2/show/record/NCT01305070 (accessed 15 August 2015).
27. Tacke J, Kieselbach D, Schulte KL. [The Freeway stent study]. Presented at the Transcatheter Cardiovascular Therapeutics Conference in Washington, D.C. September 2014.
28. Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC. Cardiovascular Interventions 2014;7(9):1048-56.
29. Randomized trial of paclitaxel eluting balloon or conventional balloon for treatment of in-stent restenosis of the superficial femoral artery in patients with symptomatic peripheral artery disease (ISAR-PEBIS). clinicaltrials.gov/ct2/show/NCT01083394 (accessed 15 August 2015).
30. Randomized trial of stenting after dilation with or without paclitaxel eluting balloon or atherectomy in patients with symptomatic peripheral artery disease. clinicaltrials.gov/ct2/show/NCT00986752 (accessed 15 August 2015).
31. A monocenter randomized clinical trial of PAClitaxel drUg-eluting BAlloon versus standard percutaneous transluminal angioplasty to reduce restenosis in patients with in-stent stenoses in the superficial femoral and proximal popliteal artery. clinicaltrials.gov/ct2/show/NCT01247402 (accessed 15 August 2015).
32. Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions. clinicaltrials.gov/ct2/show/NCT01298947 (accessed 15 August 2015).
33. Karimi A, de Boer SW, van den Heuvel D, Fioole B, Vroegindeweij D, Heyligers JMM, et al. Randomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial. Trials 2013;14:87.
34. Swedish drug-elution trial in peripheral arterial disease - a multicenter, prospective randomized controlled clinical trial based on the Swedish Vascular Registry (SWEDVASC) Platform. clinicaltrials.gov/ct2/show/NCT02051088 (accessed 15 August 2015).
35. Evaluation of the use of ACOTEC drug-eluting balloon Litos in below-the-knee arteries to treat critical limb ischemia (ACOART-BTK). clinicaltrials.gov/ct2/show/NCT02563535 (accessed 25 December 2015).
36. Prospective, multi-center and randomized controlled clinical study to verify effectiveness and safety of drug-eluting balloon in PTA procedure (AcoArt I Study). clinicaltrials.gov/ct2/show/NCT01850056 (accessed 15 August 2015).
37. Prospective, multi-center and randomized controlled clinical study to verify effectiveness and safety of drug-eluting balloon in PTA procedure of the infrapopliteal artery. clinicaltrials.gov/ct2/show/NCT02137577 (accessed 15 August 2015).
38. Advance® 18PTX® Balloon Catheter Study: treatment of lesions in superficial femoral artery/popliteal artery with a paclitaxel-coated balloon. clinicaltrials.gov/ct2/show/NCT00776906 (accessed 15 August 2015).
39. Teichgräber U. Phase III multicenter randomized controlled trial to assess the effectiveness of paclitaxel-coated Luminor balloon catheter versus uncoated balloon catheter in the superficial femoral and popliteal arteries to prevent vessel restenosis or reocclusion. Presented at the Leipzig Interventional Course; Leipzig, Germany January 2015.
40. Phase III FREERIDE study Freeway randomized angioplasty study. clinicaltrials.gov/ct2/show/NCT01960647 (accessed 15 August 2015).
41. Pivotal trial of a novel paclitaxel-coated percutaneous angioplasty balloon. clinicaltrials.gov/ct2/show/NCT01858428 (accessed 20 December 2015).
42. A prospective, multicenter, single blind, randomized, controlled Japanese population trial comparing MD02-LDCB versus standard balloon angioplasty for treatment of femoropopliteal arteries. clinicaltrials.gov/ct2/show/NCT01816412 (accessed 15 August 2015).
43. A prospective, multicenter, single blind, randomized, controlled trial comparing the Lutonix drug coated balloon versus standard balloon angioplasty for treatment of below-the-knee (BTK) arteries (Lutonix BTK trial). clinicaltrials.gov/ct2/show/NCT01870401 (accessed 15 August 2015).
44. Randomized trial of MDT-2113 drug-eluting balloon (DEB) vs. standard PTA for the treatment of atherosclerotic lesions in the superficial femoral artery and/or proximal popliteal artery. clinicaltrials.gov/ct2/show/NCT01947478 (accessed 15 August 2015).
45. Paclitaxel coated balloons for prevention of restenosis in small arteries below the knee compared to angioplasty using uncoated balloons. clinicaltrials.gov/ct2/show/NCT00696956 (accessed 15 August 2015).
46. Prospective, randomized, multicentre clinical study of the Hemoteq Ranger™ paclitaxel-coated PTA balloon catheter (Ranger DCB) in comparison to uncoated PTA balloons in femoropopliteal lesions. clinicaltrials.gov/ct2/show/NCT02013193 (accessed 15 August 2015).
47. Singapore infra-genicular angioplasty with paclitaxel-eluting balloon for critical limb ischaemia (SINGA-PACLI) trial. clinicaltrials.gov/ct2/show/NCT02129634 (accessed 15 August 2015).
48. Aquino R, Johnnides C, Makaroun M, Whittle JC, Muluk VS, Kelley ME, et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. Journal of Vascular Surgery 2001;34(6):962-70.
49. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96(2):636-45.
50. Baerlocher MO, Kennedy SA, Rajebi MR, Baerlocher FJ, Misra J, Liu D, et al. Meta-analysis of drug-eluting balloon angioplasty and drug-eluting stent placement for infrainguinal peripheral arterial disease. Journal of Vascular and Interventional Radiology 2015;26(4):459-73.
51. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;366(9501):1925-34.
52. Bradbury AW, BASIL trial investigators and participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial in perspective. Journal of Vascular Surgery 2010;51(5 Suppl):1S-4S.
53. Canaud L, Ozdemir BA, Belli AM, Loftus IM, Thompson MM, Hinchliffe RJ. Infrainguinal angioplasty with drug-eluting stents and balloons. Journal of Vascular Surgery 2014;59:1721-36.
54. Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, Kastrati A, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circulation. Cardiovascular Interventions 2012;5:582-9.
55. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. Journal of the American College of Cardiology 2013;61(24):2417-27.
56. Fowkes FGR, Housley E, Cawood EHH, Macintyre CCA, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384-92.
57. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113(11):e463-654.
59. Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC. Cardiovascular Interventions 2014;7:1048-56.
60. Jens S, Conijn AP, Koelemay MJW, Bipat S, Reekers JA. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (part 1: above the knee). European Journal of Vascular and Endovascular Surgery 2014;47(5):524-35.
61. Jens S, Conijn AP, Koelemay MJW, Bipat S, Reekers JA. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (part 2: below the knee). European Journal of Vascular and Endovascular Surgery 2014;47(5):536-44.
62. Micari A, Cioppa A, Vadala G, Castriota F, Liso A, Marchese A, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC. Cardiovascular Interventions 2012;5:331-8.
63. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). Journal of Vascular Surgery 2007;45(Suppl S):S5-67.
64. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
65. Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Braeunlich S, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. Journal of the American College of Cardiology 2011;58:1105-9.
66. Schnorr B, Albrecht T. Drug-coated balloons and their place in treating peripheral arterial disease. Expert Review of Medical Devices 2013;10(1):105-14.
67. Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, et al. Local drug delivery to prevent restenosis. Journal of Vascular Surgery 2013;57(5):1403-14.
68. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110(6):738-43.